Literature DB >> 12461074

Paradoxical severe decrease in serum HDL-cholesterol after treatment with a fibrate: reply by the authors.

M Crook, J Lynas, R Wray.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12461074      PMCID： PMC1769840          DOI： 10.1136/jcp.55.12.976

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN： 0021-9746            Impact factor:   3.411


× No keyword cloud information.
  4 in total

1.  Paradoxical severe decrease in serum HDL-cholesterol after treatment with a fibrate.

Authors:  A O Olukoga
Journal:  J Clin Pathol       Date:  2002-09       Impact factor: 3.411

2.  Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group.

Authors:  H B Rubins; S J Robins; D Collins; C L Fye; J W Anderson; M B Elam; F H Faas; E Linares; E J Schaefer; G Schectman; T J Wilt; J Wittes
Journal:  N Engl J Med       Date:  1999-08-05       Impact factor: 91.245

3.  Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease.

Authors: 
Journal:  Circulation       Date:  2000-07-04       Impact factor: 29.690

4.  A paradoxical severe decrease in serum HDL-cholesterol after treatment with a fibrate.

Authors:  M A Crook; J Lynas; R Wray
Journal:  J Clin Pathol       Date:  2000-10       Impact factor: 3.411
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.